Advertisement

Gastrointestinal Involvement in IgG4-Related Disease

  • Mitsuru SugimotoEmail author
  • Erina Suzuki
  • Kazuhiro Tasaki
  • Yuko Hashimoto
  • Hiromasa Ohira
Chapter

Abstract

IgG4-related disease (IgG4-RD) is characterized by increased serum IgG4 and swelling of several organs or nodules by infiltration of IgG4-positive plasma cells and lymphocytes, as well as fibrosis observed throughout the body. In the gastrointestinal area, autoimmune pancreatitis (AIP) and IgG4-related sclerosing cholangitis (IgG4-SC) are primarily observed. In 2010, the International Consensus Diagnostic Criteria (ICDC) for AIP were proposed, and in 2012, clinical diagnostic criteria for IgG4-SC were proposed. Nevertheless, the aetiology of IgG4-RD remains unknown, and histological diagnosis of gastrointestinal IgG4-RD remains difficult. Differentiation between gastrointestinal IgG4-RD and malignant pancreaticobiliary diseases is difficult. Steroids have become the established therapy for IgG4-RD; however, predictive relapse factors are controversial. In this chapter, we introduce the history, diagnosis and treatment of gastrointestinal IgG4-RD, as well as several challenges to ameliorating the difficulties mentioned above.

Keywords

IgG4-related disease Autoimmune pancreatitis IgG4-related sclerosing cholangitis 

References

  1. 1.
    Suzuki S, Kida S, Ohira Y, et al. [A case of Sjogren’s syndrome accompanied by lymphadenopathy and IgG4 hypergammaglobulinemia]. Ryumachi. 1993;33(3):249–54.Google Scholar
  2. 2.
    Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012;22(1):21–30.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366(6):539–51.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Hamano H, Kawa S, Ochi Y, et al. Hydronephrosis associated with retroperitoneal fibrosis and sclerosing pancreatitis. Lancet. 2002;359(9315):1403–4.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Zen Y, Onodera M, Inoue D, et al. Retroperitoneal fibrosis: a clinicopathologic study with respect to immunoglobulin G4. Am J Surg Pathol. 2009;33(12):1833–9.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Dahlgren M, Khosroshahi A, Nielsen GP, et al. Riedel’s thyroiditis and multifocal fibrosclerosis are part of the IgG4-related systemic disease spectrum. Arthritis Care Res (Hoboken). 2010;62(9):1312–8.CrossRefGoogle Scholar
  7. 7.
    Uchiyama-Tanaka Y, Mori Y, Kimura T, et al. Acute tubulointerstitial nephritis associated with autoimmune-related pancreatitis. Am J Kidney Dis. 2004;43(3):e18–25.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Takeda S, Haratake J, Kasai T, et al. IgG4-associated idiopathic tubulointerstitial nephritis complicating autoimmune pancreatitis. Nephrol Dial Transplant. 2004;19(2):474–6.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Kawano M, Saeki T, Nakashima H, et al. Proposal for diagnostic criteria for IgG4-related kidney disease. Clin Exp Nephrol. 2011;15(5):615–26.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Yamamoto M, Ohara M, Suzuki C, et al. Elevated IgG4 concentrations in serum of patients with Mikulicz’s disease. Scand J Rheumatol. 2004;33(6):432–3.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Masaki Y, Dong L, Kurose N, et al. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis. 2009;68(8):1310–5.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Kitagawa S, Zen Y, Harada K, et al. Abundant IgG4-positive plasma cell infiltration characterizes chronic sclerosing sialadenitis (Kuttner’s tumor). Am J Surg Pathol. 2005;29(6):783–91.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Unal M, Karabacak T. Kuttner’s tumour of the submandibular gland. B-ENT. 2006;2(4):197–9.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Chow TL, Chan TT, Choi CY, et al. Kuttner’s tumour (chronic sclerosing sialadenitis) of the submandibular gland: a clinical perspective. Hong Kong Med J. 2008;14(1):46–9.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Kiverniti E, Singh A, Clarke P. Kuttner’s tumour: an unusual cause of salivary gland enlargement. Hippokratia. 2008;12(1):56–8.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Kojima M, Miyawaki S, Takada S, et al. Lymphoplasmacytic infiltrate of regional lymph nodes in Kuttner’s tumor (chronic sclerosing sialadenitis): a report of 3 cases. Int J Surg Pathol. 2008;16(3):263–8.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344(10):732–8.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Okazaki K, Uchida K, Koyabu M, et al. Recent advances in the concept and diagnosis of autoimmune pancreatitis and IgG4-related disease. J Gastroenterol. 2011;46(3):277–88.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Zen Y, Harada K, Sasaki M, et al. IgG4-related sclerosing cholangitis with and without hepatic inflammatory pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis: do they belong to a spectrum of sclerosing pancreatitis? Am J Surg Pathol. 2004;28(9):1193–203.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Hamano H, Kawa S, Uehara T, et al. Immunoglobulin G4-related lymphoplasmacytic sclerosing cholangitis that mimics infiltrating hilar cholangiocarcinoma: part of a spectrum of autoimmune pancreatitis? Gastrointest Endosc. 2005;62(1):152–7.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Naitoh I, Nakazawa T, Ohara H, et al. Endoscopic transpapillary intraductal ultrasonography and biopsy in the diagnosis of IgG4-related sclerosing cholangitis. J Gastroenterol. 2009;44(11):1147–55.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Okazaki K, Uchida K, Miyoshi H, et al. Recent concepts of autoimmune pancreatitis and IgG4-related disease. Clin Rev Allergy Immunol. 2011;41(2):126–38.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Hubers LM, Vos H, Schuurman AR, et al. Annexin A11 is targeted by IgG4 and IgG1 autoantibodies in IgG4-related disease. Gut. 2018;67(4):728–35.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Shiokawa M, Kodama Y, Sekiguchi K, et al. Laminin 511 is a target antigen in autoimmune pancreatitis. Sci Transl Med. 2018;10(453). pii: eaaq0997.Google Scholar
  25. 25.
    Isenman DE, Dorrington KJ, Painter RH. The structure and function of immunoglobulin domains. II. The importance of interchain disulfide bonds and the possible role of molecular flexibility in the interaction between immunoglobulin G and complement. J Immunol. 1975;114(6):1726–9.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Bruggemann M, Williams GT, Bindon CI, et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med. 1987;166(5):1351–61.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Dangl JL, Wensel TG, Morrison SL, et al. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J. 1988;7(7):1989–94.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Tao MH, Smith RI, Morrison SL. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med. 1993;178(2):661–7.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Muraki T, Hamano H, Ochi Y, et al. Autoimmune pancreatitis and complement activation system. Pancreas. 2006;32(1):16–21.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Sugimoto M, Watanabe H, Asano T, et al. Possible participation of IgG4 in the activation of complement in IgG4-related disease with hypocomplementemia. Mod Rheumatol. 2016;26(2):251–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Konno N, Sugimoto M, Takagi T, et al. Changes in N-glycans of IgG4 and its relationship with the existence of hypocomplementemia and individual organ involvement in patients with IgG4-related disease. PLoS One. 2018;13(4):e0196163.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Yoshida K, Toki F, Takeuchi T, et al. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci. 1995;40(7):1561–8.CrossRefGoogle Scholar
  33. 33.
    Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011;40(3):352–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Irie H, Honda H, Baba S, et al. Autoimmune pancreatitis: CT and MR characteristics. AJR Am J Roentgenol. 1998;170(5):1323–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Sun GF, Zuo CJ, Shao CW, et al. Focal autoimmune pancreatitis: radiological characteristics help to distinguish from pancreatic cancer. World J Gastroenterol. 2013;19(23):3634–41.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Furuhashi N, Suzuki K, Sakurai Y, et al. Differentiation of focal-type autoimmune pancreatitis from pancreatic carcinoma: assessment by multiphase contrast-enhanced CT. Eur Radiol. 2015;25(5):1366–74.PubMedCrossRefGoogle Scholar
  37. 37.
    Lee-Felker SA, Felker ER, Kadell B, et al. Use of MDCT to differentiate autoimmune pancreatitis from ductal adenocarcinoma and interstitial pancreatitis. AJR Am J Roentgenol. 2015;205(1):2–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Zaheer A, Singh VK, Akshintala VS, et al. Differentiating autoimmune pancreatitis from pancreatic adenocarcinoma using dual-phase computed tomography. J Comput Assist Tomogr. 2014;38(1):146–52.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Okazaki K. Autoimmune pancreatitis: etiology, pathogenesis, clinical findings and treatment. The Japanese experience. JOP. 2005;6(1 Suppl):89–96.PubMedGoogle Scholar
  40. 40.
    Ishigami K, Tajima T, Nishie A, et al. MRI findings of pancreatic lymphoma and autoimmune pancreatitis: a comparative study. Eur J Radiol. 2010;74(3):e22–8.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Graziani R, Mautone S, Ambrosetti MC, et al. Autoimmune pancreatitis: multidetector-row computed tomography (MDCT) and magnetic resonance (MR) findings in the Italian experience. Radiol Med. 2014;119(8):558–71.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Kim HJ, Kim YK, Jeong WK, et al. Pancreatic duct “Icicle sign” on MRI for distinguishing autoimmune pancreatitis from pancreatic ductal adenocarcinoma in the proximal pancreas. Eur Radiol. 2015;25(6):1551–60.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Kamisawa T, Takuma K, Anjiki H, et al. Differentiation of autoimmune pancreatitis from pancreatic cancer by diffusion-weighted MRI. Am J Gastroenterol. 2010;105(8):1870–5.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Hur BY, Lee JM, Lee JE, et al. Magnetic resonance imaging findings of the mass-forming type of autoimmune pancreatitis: comparison with pancreatic adenocarcinoma. J Magn Reson Imaging. 2012;36(1):188–97.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Muhi A, Ichikawa T, Motosugi U, et al. Mass-forming autoimmune pancreatitis and pancreatic carcinoma: differential diagnosis on the basis of computed tomography and magnetic resonance cholangiopancreatography, and diffusion-weighted imaging findings. J Magn Reson Imaging. 2012;35(4):827–36.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Choi SY, Kim SH, Kang TW, et al. Differentiating mass-forming autoimmune pancreatitis from pancreatic ductal adenocarcinoma on the basis of contrast-enhanced MRI and DWI findings. AJR Am J Roentgenol. 2016;206(2):291–300.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Klauss M, Maier-Hein K, Tjaden C, et al. IVIM DW-MRI of autoimmune pancreatitis: therapy monitoring and differentiation from pancreatic cancer. Eur Radiol. 2016;26(7):2099–106.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Negrelli R, Manfredi R, Pedrinolla B, et al. Pancreatic duct abnormalities in focal autoimmune pancreatitis: MR/MRCP imaging findings. Eur Radiol. 2015;25(2):359–67.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Yanagisawa S, Fujinaga Y, Watanabe T, et al. Usefulness of three-dimensional magnetic resonance cholangiopancreatography with partial maximum intensity projection for diagnosing autoimmune pancreatitis. Pancreatology. 2017;17(4):567–71.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Kim JH, Byun JH, Kim MH, et al. Pancreatic duct in autoimmune pancreatitis: intraindividual comparison of magnetic resonance pancreatography at 1.5 T and 3.0 T. Pancreas. 2017;46(7):921–6.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Higashi T, Saga T, Nakamoto Y, et al. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET)—usefulness and limitations in “clinical reality”. Ann Nucl Med. 2003;17(4):261–79.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Zhang J, Jia G, Zuo C, et al. (18)F- FDG PET/CT helps differentiate autoimmune pancreatitis from pancreatic cancer. BMC Cancer. 2017;17(1):695.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Cheng MF, Guo YL, Yen RF, et al. Clinical utility of FDG PET/CT in patients with autoimmune pancreatitis: a case-control study. Sci Rep. 2018;8(1):3651.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Zhang J, Shao C, Wang J, et al. Autoimmune pancreatitis: whole-body 18F-FDG PET/CT findings. Abdom Imaging. 2013;38(3):543–9.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Nakamoto Y, Sakahara H, Higashi T, et al. Autoimmune pancreatitis with F-18 fluoro-2-deoxy-D-glucose PET findings. Clin Nucl Med. 1999;24(10):778–80.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Nakamoto Y, Saga T, Ishimori T, et al. FDG-PET of autoimmune-related pancreatitis: preliminary results. Eur J Nucl Med. 2000;27(12):1835–8.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Nakajo M, Jinnouchi S, Fukukura Y, et al. The efficacy of whole-body FDG-PET or PET/CT for autoimmune pancreatitis and associated extrapancreatic autoimmune lesions. Eur J Nucl Med Mol Imaging. 2007;34(12):2088–95.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Ozaki Y, Oguchi K, Hamano H, et al. Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography. J Gastroenterol. 2008;43(2):144–51.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Takahashi H, Yamashita H, Morooka M, et al. The utility of FDG-PET/CT and other imaging techniques in the evaluation of IgG4-related disease. Joint Bone Spine. 2014;81(4):331–6.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Zhao Z, Wang Y, Guan Z, et al. Utility of FDG-PET/CT in the diagnosis of IgG4-related diseases. Clin Exp Rheumatol. 2016;34(1):119–25.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Shigekawa M, Yamao K, Sawaki A, et al. Is (18)F-fluorodeoxyglucose positron emission tomography meaningful for estimating the efficacy of corticosteroid therapy in patients with autoimmune pancreatitis? J Hepatobiliary Pancreat Sci. 2010;17(3):269–74.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Hocke M, Ignee A, Dietrich CF. Contrast-enhanced endoscopic ultrasound in the diagnosis of autoimmune pancreatitis. Endoscopy. 2011;43(2):163–5.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Cho MK, Moon SH, Song TJ, et al. Contrast-enhanced endoscopic ultrasound for differentially diagnosing autoimmune pancreatitis and pancreatic cancer. Gut Liver. 2018;12(5):591–6.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Imazu H, Kanazawa K, Mori N, et al. Novel quantitative perfusion analysis with contrast-enhanced harmonic EUS for differentiation of autoimmune pancreatitis from pancreatic carcinoma. Scand J Gastroenterol. 2012;47(7):853–60.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Kobayashi G, Fujita N, Noda Y, et al. Vascular image in autoimmune pancreatitis by contrast-enhanced color-Doppler endoscopic ultrasonography: comparison with pancreatic cancer. Endosc Ultrasound. 2014;3(Suppl 1):S13.PubMedPubMedCentralGoogle Scholar
  66. 66.
    Kanno A, Masamune A, Shimosegawa T. Endoscopic approaches for the diagnosis of autoimmune pancreatitis. Dig Endosc. 2015;27(2):250–8.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Wakabayashi T, Kawaura Y, Satomura Y, et al. Clinical and imaging features of autoimmune pancreatitis with focal pancreatic swelling or mass formation: comparison with so-called tumor-forming pancreatitis and pancreatic carcinoma. Am J Gastroenterol. 2003;98(12):2679–87.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Nakazawa T, Ohara H, Sano H, et al. Difficulty in diagnosing autoimmune pancreatitis by imaging findings. Gastrointest Endosc. 2007;65(1):99–108.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Nishino T, Oyama H, Toki F, et al. Differentiation between autoimmune pancreatitis and pancreatic carcinoma based on endoscopic retrograde cholangiopancreatography findings. J Gastroenterol. 2010;45(9):988–96.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Kamisawa T, Imai M, Yui Chen P, et al. Strategy for differentiating autoimmune pancreatitis from pancreatic cancer. Pancreas. 2008;37(3):e62–7.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Kamisawa T, Tu Y, Egawa N, et al. Involvement of pancreatic and bile ducts in autoimmune pancreatitis. World J Gastroenterol. 2006;12(4):612–4.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Okazaki K, Kawa S, Kamisawa T, et al. Clinical diagnostic criteria of autoimmune pancreatitis: revised proposal. J Gastroenterol. 2006;41(7):626–31.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Iwasaki S, Kamisawa T, Koizumi S, et al. Characteristic findings of endoscopic retrograde cholangiopancreatography in autoimmune pancreatitis. Gut Liver. 2015;9(1):113–7.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Mizuno N, Bhatia V, Hosoda W, et al. Histological diagnosis of autoimmune pancreatitis using EUS-guided trucut biopsy: a comparison study with EUS-FNA. J Gastroenterol. 2009;44(7):742–50.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Iwashita T, Yasuda I, Doi S, et al. Use of samples from endoscopic ultrasound-guided 19-gauge fine-needle aspiration in diagnosis of autoimmune pancreatitis. Clin Gastroenterol Hepatol. 2012;10(3):316–22.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Ishikawa T, Itoh A, Kawashima H, et al. Endoscopic ultrasound-guided fine needle aspiration in the differentiation of type 1 and type 2 autoimmune pancreatitis. World J Gastroenterol. 2012;18(29):3883–8.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Kanno A, Ishida K, Hamada S, et al. Diagnosis of autoimmune pancreatitis by EUS-FNA by using a 22-gauge needle based on the International Consensus Diagnostic Criteria. Gastrointest Endosc. 2012;76(3):594–602.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Imai K, Matsubayashi H, Fukutomi A, et al. Endoscopic ultrasonography-guided fine needle aspiration biopsy using 22-gauge needle in diagnosis of autoimmune pancreatitis. Dig Liver Dis. 2011;43(11):869–74.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Kanno A, Masamune A, Fujishima F, et al. Diagnosis of autoimmune pancreatitis by EUS-guided FNA using a 22-gauge needle: a prospective multicenter study. Gastrointest Endosc. 2016;84(5):797–804 e791.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Morishima T, Kawashima H, Ohno E, et al. Prospective multicenter study on the usefulness of EUS-guided FNA biopsy for the diagnosis of autoimmune pancreatitis. Gastrointest Endosc. 2016;84(2):241–8.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Sugimoto M, Takagi T, Suzuki R, et al. Endoscopic ultrasonography-guided fine needle aspiration can be used to rule out malignancy in autoimmune pancreatitis patients. J Ultrasound Med. 2017;36(11):2237–44.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Runge TM, Hart PA, Sasatomi E, et al. Diagnosis of autoimmune pancreatitis using new, flexible EUS core biopsy needles: report of 2 cases. Gastrointest Endosc. 2017;85(6):1311–2.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Bhattacharya A, Cruise M, Chahal P. Endoscopic ultrasound guided 22 gauge core needle biopsy for the diagnosis of autoimmune pancreatitis. Pancreatology. 2018;18(2):168–9.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Okazaki K, Chari ST, Frulloni L, et al. International consensus for the treatment of autoimmune pancreatitis. Pancreatology. 2017;17(1):1–6.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Hart PA, Kamisawa T, Brugge WR, et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut. 2013;62(12):1771–6.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Kamisawa T, Yoshiike M, Egawa N, et al. Treating patients with autoimmune pancreatitis: results from a long-term follow-up study. Pancreatology. 2005;5(2–3):234–8; discussion 238–240.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Kamisawa T, Shimosegawa T, Okazaki K, et al. Standard steroid treatment for autoimmune pancreatitis. Gut. 2009;58(11):1504–7.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Ozden I, Dizdaroglu F, Poyanli A, et al. Spontaneous regression of a pancreatic head mass and biliary obstruction due to autoimmune pancreatitis. Pancreatology. 2005;5(2–3):300–3.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Maire F, Le Baleur Y, Rebours V, et al. Outcome of patients with type 1 or 2 autoimmune pancreatitis. Am J Gastroenterol. 2011;106(1):151–6.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Araki J, Tsujimoto F, Ohta T, et al. Natural course of autoimmune pancreatitis without steroid therapy showing hypoechoic masses in the uncinate process and tail of the pancreas on ultrasonography. J Ultrasound Med. 2006;25(8):1063–7.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Wakabayashi T, Kawaura Y, Satomura Y, et al. Long-term prognosis of duct-narrowing chronic pancreatitis: strategy for steroid treatment. Pancreas. 2005;30(1):31–9.PubMedPubMedCentralGoogle Scholar
  92. 92.
    Kubota K, Iida H, Fujisawa T, et al. Clinical factors predictive of spontaneous remission or relapse in cases of autoimmune pancreatitis. Gastrointest Endosc. 2007;66(6):1142–51.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Kamisawa T, Okazaki K, Kawa S, et al. Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 III. Treatment and prognosis of autoimmune pancreatitis. J Gastroenterol. 2014;49(6):961–70.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Kubota K, Kamisawa T, Hirano K, et al. Clinical course of type 1 autoimmune pancreatitis patients without steroid treatment: a Japanese multicenter study of 97 patients. J Hepatobiliary Pancreat Sci. 2018;25(4):223–30.PubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    Pearson RK, Longnecker DS, Chari ST, et al. Controversies in clinical pancreatology: autoimmune pancreatitis: does it exist? Pancreas. 2003;27(1):1–13.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Finkelberg DL, Sahani D, Deshpande V, et al. Autoimmune pancreatitis. N Engl J Med. 2006;355(25):2670–6.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Ghazale A, Chari ST. Optimising corticosteroid treatment for autoimmune pancreatitis. Gut. 2007;56(12):1650–2.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Park DH, Kim MH, Oh HB, et al. Substitution of aspartic acid at position 57 of the DQbeta1 affects relapse of autoimmune pancreatitis. Gastroenterology. 2008;134(2):440–6.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Nishino T, Toki F, Oyama H, et al. Biliary tract involvement in autoimmune pancreatitis. Pancreas. 2005;30(1):76–82.PubMedPubMedCentralGoogle Scholar
  100. 100.
    Chari ST, Smyrk TC, Levy MJ, et al. Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin Gastroenterol Hepatol. 2006;4(8):1010–6; quiz 1934.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Khosroshahi A, Wallace ZS, Crowe JL, et al. International Consensus Guidance Statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol. 2015;67(7):1688–99.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Kamisawa T, Okazaki K, Kawa S, et al. Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP. J Gastroenterol. 2010;45(5):471–7.PubMedCrossRefPubMedCentralGoogle Scholar
  103. 103.
    Takuma K, Kamisawa T, Tabata T, et al. Short-term and long-term outcomes of autoimmune pancreatitis. Eur J Gastroenterol Hepatol. 2011;23(2):146–52.PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    Kountz SL, Cohn R. Initial treatment of renal allografts with large intrarenal doses of immunosuppressive drugs. Lancet. 1969;1(7590):338–40.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Cathcart ES, Idelson BA, Scheinberg MA, et al. Beneficial effects of methylprednisolone “pulse” therapy in diffuse proliferative lupus nephritis. Lancet. 1976;1(7952):163–6.PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    Vichyanond P, Irvin CG, Larsen GL, et al. Penetration of corticosteroids into the lung: evidence for a difference between methylprednisolone and prednisolone. J Allergy Clin Immunol. 1989;84(6 Pt 1):867–73.PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Matsushita M, Yamashina M, Ikeura T, et al. Effective steroid pulse therapy for the biliary stenosis caused by autoimmune pancreatitis. Am J Gastroenterol. 2007;102(1):220–1.PubMedPubMedCentralGoogle Scholar
  108. 108.
    Tomiyama T, Uchida K, Matsushita M, et al. Comparison of steroid pulse therapy and conventional oral steroid therapy as initial treatment for autoimmune pancreatitis. J Gastroenterol. 2011;46(5):696–704.PubMedCrossRefPubMedCentralGoogle Scholar
  109. 109.
    Sugimoto M, Takagi T, Suzuki R, et al. Efficacy of steroid pulse therapy for autoimmune pancreatitis type 1: a retrospective study. PLoS One. 2015;10(9):e0138604.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    You MW, Kim JH, Byun JH, et al. Relapse of IgG4-related sclerosing cholangitis after steroid therapy: image findings and risk factors. Eur Radiol. 2014;24(5):1039–48.PubMedCrossRefPubMedCentralGoogle Scholar
  111. 111.
    Nishimori I, Tamakoshi A, Otsuki M. Prevalence of autoimmune pancreatitis in Japan from a nationwide survey in 2002. J Gastroenterol. 2007;42(Suppl 18):6–8.PubMedCrossRefPubMedCentralGoogle Scholar
  112. 112.
    Ito T, Nishimori I, Inoue N, et al. Treatment for autoimmune pancreatitis: consensus on the treatment for patients with autoimmune pancreatitis in Japan. J Gastroenterol. 2007;42(Suppl 18):50–8.PubMedCrossRefPubMedCentralGoogle Scholar
  113. 113.
    Kawa S, Hamano H, Ozaki Y, et al. Long-term follow-up of autoimmune pancreatitis: characteristics of chronic disease and recurrence. Clin Gastroenterol Hepatol. 2009;7(11 Suppl):S18–22.PubMedCrossRefPubMedCentralGoogle Scholar
  114. 114.
    Ohno Y, Kumagi T, Yokota T, et al. Early pancreatic volume reduction on CT predicts relapse in patients with type 1 autoimmune pancreatitis treated with steroids. Orphanet J Rare Dis. 2016;11(1):103.PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    Shimizu K, Tahara J, Takayama Y, et al. Assessment of the rate of decrease in serum IgG4 level of autoimmune pancreatitis patients in response to initial steroid therapy as a predictor of subsequent relapse. Pancreas. 2016;45(9):1341–6.PubMedCrossRefPubMedCentralGoogle Scholar
  116. 116.
    Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25(9):1181–92.PubMedCrossRefPubMedCentralGoogle Scholar
  117. 117.
    Waldram R, Kopelman H, Tsantoulas D, et al. Chronic pancreatitis, sclerosing cholangitis, and sicca complex in two siblings. Lancet. 1975;1(7906):550–2.PubMedCrossRefPubMedCentralGoogle Scholar
  118. 118.
    Sjogren I, Wengle B, Korsgren M. Primary sclerosing cholangitis associated with fibrosis of the submandibular glands and the pancreas. Acta Med Scand. 1979;205(1–2):139–41.PubMedPubMedCentralGoogle Scholar
  119. 119.
    Kawaguchi K, Koike M, Tsuruta K, et al. Lymphoplasmacytic sclerosing pancreatitis with cholangitis: a variant of primary sclerosing cholangitis extensively involving pancreas. Hum Pathol. 1991;22(4):387–95.PubMedCrossRefPubMedCentralGoogle Scholar
  120. 120.
    Nakazawa T, Ohara H, Yamada T, et al. Atypical primary sclerosing cholangitis cases associated with unusual pancreatitis. Hepatogastroenterology. 2001;48(39):625–30.PubMedPubMedCentralGoogle Scholar
  121. 121.
    Nakazawa T, Ohara H, Sano H, et al. Clinical differences between primary sclerosing cholangitis and sclerosing cholangitis with autoimmune pancreatitis. Pancreas. 2005;30(1):20–5.PubMedPubMedCentralGoogle Scholar
  122. 122.
    Hirano K, Tada M, Isayama H, et al. Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut. 2007;56(12):1719–24.PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134(3):706–15.PubMedCrossRefPubMedCentralGoogle Scholar
  124. 124.
    Kamisawa T, Funata N, Hayashi Y, et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol. 2003;38(10):982–4.PubMedCrossRefPubMedCentralGoogle Scholar
  125. 125.
    Ohara H, Nakazawa T, Sano H, et al. Systemic extrapancreatic lesions associated with autoimmune pancreatitis. Pancreas. 2005;31(3):232–7.PubMedCrossRefPubMedCentralGoogle Scholar
  126. 126.
    Hamano H, Arakura N, Muraki T, et al. Prevalence and distribution of extrapancreatic lesions complicating autoimmune pancreatitis. J Gastroenterol. 2006;41(12):1197–205.PubMedCrossRefPubMedCentralGoogle Scholar
  127. 127.
    Naitoh I, Nakazawa T, Ohara H, et al. Clinical significance of extrapancreatic lesions in autoimmune pancreatitis. Pancreas. 2010;39(1):e1–5.PubMedCrossRefPubMedCentralGoogle Scholar
  128. 128.
    Stone JH, Khosroshahi A, Deshpande V, et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum. 2012;64(10):3061–7.PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Ohara H, Okazaki K, Tsubouchi H, et al. Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012. J Hepatobiliary Pancreat Sci. 2012;19(5):536–42.PubMedCrossRefPubMedCentralGoogle Scholar
  130. 130.
    Kawakami H, Zen Y, Kuwatani M, et al. IgG4-related sclerosing cholangitis and autoimmune pancreatitis: histological assessment of biopsies from Vater’s ampulla and the bile duct. J Gastroenterol Hepatol. 2010;25(10):1648–55.PubMedCrossRefPubMedCentralGoogle Scholar
  131. 131.
    Iwasaki S, Kamisawa T, Koizumi S, et al. Assessment in steroid trial for IgG4-related sclerosing cholangitis. Adv Med Sci. 2015;60(2):211–5.PubMedCrossRefPubMedCentralGoogle Scholar
  132. 132.
    Nakazawa T, Ohara H, Sano H, et al. Schematic classification of sclerosing cholangitis with autoimmune pancreatitis by cholangiography. Pancreas. 2006;32(2):229.PubMedCrossRefPubMedCentralGoogle Scholar
  133. 133.
    Tanaka A, Tazuma S, Okazaki K, et al. Clinical features, response to treatment, and outcomes of IgG4-related sclerosing cholangitis. Clin Gastroenterol Hepatol. 2017;15(6):920–926 e923.PubMedCrossRefPubMedCentralGoogle Scholar
  134. 134.
    Mo Z, Ramen K, Shan Y, et al. Localized intrahepatic IgG4-related sclerosing cholangitis (IgG4-SC) as an additional type of IgG4-SC: a systematic analysis of 12 cases. Scand J Gastroenterol. 2018;53(3):312–8.PubMedCrossRefPubMedCentralGoogle Scholar
  135. 135.
    Hirano K, Tada M, Isayama H, et al. Endoscopic evaluation of factors contributing to intrapancreatic biliary stricture in autoimmune pancreatitis. Gastrointest Endosc. 2010;71(1):85–90.PubMedCrossRefPubMedCentralGoogle Scholar
  136. 136.
    Nakazawa T, Ikeda Y, Kawaguchi Y, et al. Isolated intrapancreatic IgG4-related sclerosing cholangitis. World J Gastroenterol. 2015;21(4):1334–43.PubMedPubMedCentralCrossRefGoogle Scholar
  137. 137.
    Nakazawa T, Ohara H, Sano H, et al. Cholangiography can discriminate sclerosing cholangitis with autoimmune pancreatitis from primary sclerosing cholangitis. Gastrointest Endosc. 2004;60(6):937–44.PubMedCrossRefPubMedCentralGoogle Scholar
  138. 138.
    Zen Y, Kawakami H, Kim JH. IgG4-related sclerosing cholangitis: all we need to know. J Gastroenterol. 2016;51(4):295–312.PubMedCrossRefPubMedCentralGoogle Scholar
  139. 139.
    Notohara K, Burgart LJ, Yadav D, et al. Idiopathic chronic pancreatitis with periductal lymphoplasmacytic infiltration: clinicopathologic features of 35 cases. Am J Surg Pathol. 2003;27(8):1119–27.PubMedCrossRefPubMedCentralGoogle Scholar
  140. 140.
    Hyodo N, Hyodo T. Ultrasonographic evaluation in patients with autoimmune-related pancreatitis. J Gastroenterol. 2003;38(12):1155–61.PubMedCrossRefPubMedCentralGoogle Scholar
  141. 141.
    Kawa S, Okazaki K, Kamisawa T, et al. Japanese consensus guidelines for management of autoimmune pancreatitis: II. Extrapancreatic lesions, differential diagnosis. J Gastroenterol. 2010;45(4):355–69.PubMedCrossRefPubMedCentralGoogle Scholar
  142. 142.
    Moon SH, Kim MH. The role of endoscopy in the diagnosis of autoimmune pancreatitis. Gastrointest Endosc. 2012;76(3):645–56.PubMedCrossRefPubMedCentralGoogle Scholar
  143. 143.
    Tabata T, Kamisawa T, Hara S, et al. Differentiating immunoglobulin g4-related sclerosing cholangitis from hilar cholangiocarcinoma. Gut Liver. 2013;7(2):234–8.PubMedPubMedCentralCrossRefGoogle Scholar
  144. 144.
    Kuwatani M, Kawakami H, Zen Y, et al. Difference from bile duct cancer and relationship between bile duct wall thickness and serum IgG/IgG4 levels in IgG4-related sclerosing cholangitis. Hepatogastroenterology. 2014;61(135):1852–6.PubMedPubMedCentralGoogle Scholar
  145. 145.
    Kamisawa T, Ohara H, Kim MH, et al. Role of endoscopy in the diagnosis of autoimmune pancreatitis and immunoglobulin G4-related sclerosing cholangitis. Dig Endosc. 2014;26(5):627–35.PubMedCrossRefPubMedCentralGoogle Scholar
  146. 146.
    Ohara H, Nakazawa T, Kawa S, et al. Establishment of a serum IgG4 cut-off value for the differential diagnosis of IgG4-related sclerosing cholangitis: a Japanese cohort. J Gastroenterol Hepatol. 2013;28(7):1247–51.PubMedCrossRefPubMedCentralGoogle Scholar
  147. 147.
    Boonstra K, Culver EL, de Buy Wenniger LM, et al. Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. Hepatology. 2014;59(5):1954–63.PubMedPubMedCentralCrossRefGoogle Scholar
  148. 148.
    Tanaka A, Tazuma S, Nakazawa T, et al. No negative impact of serum IgG4 levels on clinical outcome in 435 patients with primary sclerosing cholangitis from Japan. J Hepatobiliary Pancreat Sci. 2017;24(4):217–25.PubMedCrossRefPubMedCentralGoogle Scholar
  149. 149.
    Tanaka A, Tazuma S, Okazaki K, et al. Nationwide survey for primary sclerosing cholangitis and IgG4-related sclerosing cholangitis in Japan. J Hepatobiliary Pancreat Sci. 2014;21(1):43–50.PubMedCrossRefPubMedCentralGoogle Scholar
  150. 150.
    Bjornsson E, Chari S, Silveira M, et al. Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. Am J Ther. 2011;18(3):198–205.PubMedCrossRefPubMedCentralGoogle Scholar
  151. 151.
    Mendes FD, Jorgensen R, Keach J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2006;101(9):2070–5.PubMedCrossRefPubMedCentralGoogle Scholar
  152. 152.
    Alswat K, Al-Harthy N, Mazrani W, et al. The spectrum of sclerosing cholangitis and the relevance of IgG4 elevations in routine practice. Am J Gastroenterol. 2012;107(1):56–63.PubMedCrossRefPubMedCentralGoogle Scholar
  153. 153.
    Berntsen NL, Klingenberg O, Juran BD, et al. Association between HLA haplotypes and increased serum levels of IgG4 in patients with primary sclerosing cholangitis. Gastroenterology. 2015;148(5):924–927 e922.PubMedPubMedCentralCrossRefGoogle Scholar
  154. 154.
    Benito de Valle M, Muller T, Bjornsson E, et al. The impact of elevated serum IgG4 levels in patients with primary sclerosing cholangitis. Dig Liver Dis. 2014;46(10):903–8.PubMedCrossRefGoogle Scholar
  155. 155.
    Azeem N, Ajmera V, Hameed B, et al. Hilar cholangiocarcinoma associated with immunoglobulin G4-positive plasma cells and elevated serum immunoglobulin G4 levels. Hepatol Commun. 2018;2(4):349–53.PubMedPubMedCentralCrossRefGoogle Scholar
  156. 156.
    Loftus EV Jr, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54(1):91–6.PubMedPubMedCentralCrossRefGoogle Scholar
  157. 157.
    Sano H, Nakazawa T, Ando T, et al. Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci. 2011;18(2):154–61.PubMedCrossRefGoogle Scholar
  158. 158.
    Xiao J, Xu P, Li B, et al. Analysis of clinical characteristics and treatment of immunoglobulin G4-associated cholangitis: a retrospective cohort study of 39 IAC patients. Medicine (Baltimore). 2018;97(8):e9767.CrossRefGoogle Scholar
  159. 159.
    Kato A, Naitoh I, Miyabe K, et al. Differential diagnosis of cholangiocarcinoma and IgG4-related sclerosing cholangitis by fluorescence in situ hybridization using transpapillary forceps biopsy specimens. J Hepatobiliary Pancreat Sci. 2018;25(3):188–94.PubMedCrossRefGoogle Scholar
  160. 160.
    Umemura T, Zen Y, Hamano H, et al. Immunoglobin G4-hepatopathy: association of immunoglobin G4-bearing plasma cells in liver with autoimmune pancreatitis. Hepatology. 2007;46(2):463–71.PubMedCrossRefGoogle Scholar
  161. 161.
    Deshpande V, Sainani NI, Chung RT, et al. IgG4-associated cholangitis: a comparative histological and immunophenotypic study with primary sclerosing cholangitis on liver biopsy material. Mod Pathol. 2009;22(10):1287–95.PubMedCrossRefGoogle Scholar
  162. 162.
    Naitoh I, Zen Y, Nakazawa T, et al. Small bile duct involvement in IgG4-related sclerosing cholangitis: liver biopsy and cholangiography correlation. J Gastroenterol. 2011;46(2):269–76.PubMedCrossRefGoogle Scholar
  163. 163.
    Portmann B, Zen Y. Inflammatory disease of the bile ducts-cholangiopathies: liver biopsy challenge and clinicopathological correlation. Histopathology. 2012;60(2):236–48.PubMedCrossRefGoogle Scholar
  164. 164.
    Chiba K, Kamisawa T, Kuruma S, et al. Major and minor duodenal papillae in autoimmune pancreatitis. Pancreas. 2014;43(8):1299–302.PubMedCrossRefPubMedCentralGoogle Scholar
  165. 165.
    Kamisawa T, Tu Y, Nakajima H, et al. Usefulness of biopsying the major duodenal papilla to diagnose autoimmune pancreatitis: a prospective study using IgG4-immunostaining. World J Gastroenterol. 2006;12(13):2031–3.PubMedPubMedCentralCrossRefGoogle Scholar
  166. 166.
    Kubota K, Iida H, Fujisawa T, et al. Clinical significance of swollen duodenal papilla in autoimmune pancreatitis. Pancreas. 2007;35(4):e51–60.PubMedCrossRefPubMedCentralGoogle Scholar
  167. 167.
    Kim MH, Moon SH, Kamisawa T. Major duodenal papilla in autoimmune pancreatitis. Dig Surg. 2010;27(2):110–4.PubMedCrossRefPubMedCentralGoogle Scholar
  168. 168.
    Moon SH, Kim MH, Lee JK, et al. Development of a scoring system for differentiating IgG4-related sclerosing cholangitis from primary sclerosing cholangitis. J Gastroenterol. 2017;52(4):483–93.PubMedCrossRefPubMedCentralGoogle Scholar
  169. 169.
    Moon SH, Kim MH. Autoimmune pancreatitis: role of endoscopy in diagnosis and treatment. Gastrointest Endosc Clin N Am. 2013;23(4):893–915.PubMedCrossRefPubMedCentralGoogle Scholar
  170. 170.
    Bi Y, Hart PA, Law R, et al. Obstructive jaundice in autoimmune pancreatitis can be safely treated with corticosteroids alone without biliary stenting. Pancreatology. 2016;16(3):391–6.PubMedCrossRefPubMedCentralGoogle Scholar
  171. 171.
    Liu W, Chen W, He X, et al. Poor response of initial steroid therapy for IgG4-related sclerosing cholangitis with multiple organs affected. Medicine (Baltimore). 2017;96(12):e6400.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Mitsuru Sugimoto
    • 1
    Email author
  • Erina Suzuki
    • 2
  • Kazuhiro Tasaki
    • 2
  • Yuko Hashimoto
    • 2
  • Hiromasa Ohira
    • 1
  1. 1.Department of GastroenterologyFukushima Medical University School of MedicineFukushimaJapan
  2. 2.Department of Diagnostic PathologyFukushima Medical University School of MedicineFukushimaJapan

Personalised recommendations